- Home
- SBFG vs FATE Comparison
SBFG vs FATE Comparison
Compare SBFG & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBFG | FATE |
|---|---|---|
| Founded | 1983 | 2007 |
| Country | United States | United States |
| Employees | N/A | 161 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.8M | 125.6M |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SBFG | FATE |
|---|---|---|
| Price | $20.02 | $1.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 9.2K | ★ 1.4M |
| Earning Date | 04-30-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | 27.33 | ★ 29.88 |
| EPS | ★ 2.19 | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.05 |
| P/E Ratio | $9.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.10 | $0.66 |
| 52 Week High | $23.93 | $1.94 |
Technical Indicators
Market Signals| Indicator | SBFG | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 38.22 | 39.62 |
| Support Level | $19.69 | $0.96 |
| Resistance Level | $21.60 | $1.16 |
| Average True Range (ATR) | 0.49 | 0.09 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 35.51 | 14.77 |
Price Performance
Historical ComparisonAbout SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in single segment which is Banking.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.